Atibuclimab Biosimilar - Research Grade

Human

CD14

>1mg/ml

Human IgG4

Bulk Anti-Human CD14 (UCHM-1) Antibody (ICH1009)

https://www.imgt.org/mAb-DB/

ICH3002

P08571

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of atibuclimab (IC14), an antibody directed against human CD14, supplied strictly for research use. It is built as a human IgG4-format molecule targeting CD14 and is offered as a bench reagent rather than as the clinical drug. Because it reproduces the binding specificity of the originator without any conjugation, it is well suited to work that needs a defined anti-CD14 tool: as a blocking or neutralising reagent against CD14-dependent signaling, as a positive control or benchmarking comparator in binding and functional assays, and as a fixed reference input for assay development and standardisation. The human IgG4 backbone provides a relatively inert, low-effector-function Fc, which is useful when the goal is to interrogate ligand blockade rather than Fc-mediated killing. It is manufactured to low-endotoxin research grade (typically under 1 EU/mg, with ultra-low-endotoxin options under 0.5 EU/mg) and is available in bulk milligram-to-gram quantities to support in-vitro and preclinical programs. It is not for human or veterinary use. CD14 is a glycosylphosphatidylinositol-anchored myeloid surface protein, expressed mainly on monocytes, macrophages and neutrophils, that also circulates as a soluble form. It functions as a pattern-recognition co-receptor central to innate immunity. Working together with LPS-binding protein (LBP), CD14 captures bacterial lipopolysaccharide and delivers it to the MD-2/TLR4 complex, triggering NF-kB-driven proinflammatory signaling. CD14 similarly supports TLR2-dependent recognition of bacterial lipopeptides and can engage a range of other pathogen-associated and damage-associated molecular patterns (PAMPs and DAMPs). Through these interactions CD14 amplifies cytokine production and shapes both antimicrobial defense and maladaptive inflammation. Because it sits upstream of multiple TLR pathways, CD14 is studied as a node for modulating inflammation in sepsis, acute lung injury and related conditions.

cluster of differentiation 14

Detects human CD14. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Atibuclimab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Atibuclimab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Atibuclimab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Atibuclimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Atibuclimab that binds human CD14.